Omicron BA.2 Subvariant is More Transmissible

Omicron BA.2 subvariant seems to be more transmissible than BA.1. It also possesses immune-evasive properties that further reduce the protective effect of vaccination against infection. 

On 26 November 2021, WHO had designated B.1.1.529 variant of SARS-CoV-2 as a Variant of concern (VOC), and named Omicron.  

As on date, Omicron includes Pango lineage B.1.1.529 and descendent Pango lineages BA.1, BA.1.1, BA.2 and BA.3. The defining mutations fully overlaps with the lineage BA.1. The descendent lineage BA.2 differs from BA.1 in some of the mutations, including in the spike protein.  

BA.2 variant is increasing in many countries. In several countries, two Omicron subvariants are observed BA.1 and BA.2. 

In Denmark, BA.2 has rapidly replaced BA.1 and has become the dominant subvariant. In a recent nationwide study of Danish households, the secondary attack rate (SAR) was estimated as 29% and 39% in households infected with Omicron BA.1 and BA.2, respectively.  

BA.2 was found to be associated with an increased susceptibility of infection for unvaccinated individuals (Odds Ratio 2.19), fully vaccinated individuals (OR 2.45) and booster-vaccinated individuals (OR 2.99), compared to BA.1.  

The researchers also found an increased transmissibility from unvaccinated primary cases in BA.2 households when compared to BA.1 households. The pattern of increased transmissibility in BA.2 households was not observed for fully vaccinated and booster-vaccinated primary cases.   

In conclusion, Omicron BA.2 subvariant seems to be more transmissible than BA.1. It also possesses immune-evasive properties that further reduce the protective effect of vaccination against infection.  

***

Sources:  

  1. WHO 2022. Tracking SARS-CoV-2 variants. Available at https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ Accessed on 04 February 2022.  
  1. Lyngse FP, et al 2022. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. Preprint medRxiv. Posted January 30, 2022. DOI: https://doi.org/10.1101/2022.01.28.22270044 

***

Don't miss

Interferon-β for Treatment of COVID-19: Subcutaneous Administration more Effective

Results from the phase2 trial support the view that...

COVID‑19: National Lockdown in the UK

To protect the NHS and save lives., National Lockdown...

A Novel Approach to ‘Repurpose’ Existing Drugs For COVID-19

A combination of biological and computational approach to study...

Did the SARS CoV-2 Virus Originate in Laboratory?

There is no clarity on the natural origin of...

‘Bradykinin Hypothesis’ Explains the Exaggerated Inflammatory Response in COVID-19

A novel mechanism to explain the different unrelated symptoms...

Stay in touch:

92,144FansLike
45,781FollowersFollow
1,772FollowersFollow
51SubscribersSubscribe

Newsletter

Latest

COVID-19 in 2025  

The unprecedented COVID-19 pandemic spanning over three years claimed...

CoViNet: A New Network of Global Laboratories for Coronaviruses 

A new global network of laboratories for coronaviruses, CoViNet,...

COVID-19: Severe lung infection affects heart through “cardiac macrophage shift” 

It is known that COVID-19 increases the risk of...

JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25...

COVID-19: JN.1 sub-variant has higher transmissibility and immune escape ability 

Spike mutation (S: L455S) is hallmark mutation of JN.1...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Humans and Viruses: A Brief History of Their Complex Relationship And Implications for COVID-19

Humans would not have existed without viruses because viral protein plays a key role in the development of human embryo. However, at times, they...

COVID-19: Severe lung infection affects heart through “cardiac macrophage shift” 

It is known that COVID-19 increases the risk of heart attack, stroke, and Long COVID but what was not known is whether the damage...

MHRA Approves Moderna’s mRNA COVID-19 Vaccine

Medicines and Healthcare products Regulatory Agency (MHRA), the regulator of all medicines and medical devices in the UK has approved Moderna’s COVID-19 vaccine after...